Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)

BACKGROUND: The global phase 3 studies of golimumab [PURSUIT-SC and PURSUIT-maintenance (M)], an anti-tumor necrosis factor-α (anti-TNFα) antibody, have demonstrated clinical efficacy and safety as induction and maintenance therapies in patients with moderate to severely active ulcerative colitis (U...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibi, Toshifumi, Imai, Yuya, Senoo, Asako, Ohta, Kentaro, Ukyo, Yoshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article—Alimentary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606947/
https://www.ncbi.nlm.nih.gov/pubmed/28324167
http://dx.doi.org/10.1007/s00535-017-1326-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606947/
https://www.ncbi.nlm.nih.gov/pubmed/28324167
http://dx.doi.org/10.1007/s00535-017-1326-1

Ejemplares similares